Doctor’s Orders: The Search for a Workable Pleading Standard in Hikma v. Amarin

Pharmaceutical patent litigators are no strangers to the delicate dance between the Hatch-Waxman Act and 35 U.S.C. § 271(b). On one side of this statutory tightrope lies the Hatch-Waxman Act’s Section VIII pathway, which was designed to expedite affordable generic competition by allowing manufacturers to seek Food and Drug Administration (FDA) approval solely for unpatented indications—the proverbial “skinny label.” On the flip side lies Section 271(b), which imposes strict liability on anyone who “actively induces” patent infringement.

The inherent friction between these two statutes is a common source of litigation. Generics are statutorily encouraged to enter the market for unpatented uses, yet they face severe liability if they are deemed to be encouraging the medical community to prescribe that identical pill for a carved-out, patented use. This has created a question: how can a generic company lawfully launch and market a carved-out product without its actions, press releases, or basic industry terminology crossing the line into specific intent to induce infringement?

To answer that question, on April 29, the Supreme Court will hear oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

The Case

Amarin’s drug, Vascepa, has an unpatented 2012 indication for severe hypertriglyceridemia and a patented 2019 indication for reducing cardiovascular (CV) risk. Hikma launched its generic in 2020 with an FDA-approved “skinny label” that dutifully carved out the patented CV indication.

If the label alone were the end of the story, Hikma would be squarely shielded from inducement liability. In fact, the district court relied heavily on this premise when it initially dismissed Amarin’s complaint for failure to state a claim. But Amarin’s allegations hinged on extra-label communications: Hikma’s press releases, web content, the omission of original label limitations, references to Vascepa’s massive overall sales figures, and the use of the loaded phrase “generic equivalent.” Amarin argued—and the Federal Circuit agreed, reversing the district court’s dismissal—that these factors implied interchangeability for all uses, plausibly pleading specific intent to induce infringement.

The core tension before the Court lies in determining what actually constitutes “active inducement” when a generic company is nominally complying with FDA carve-out rules. Are generic companies required to market their drugs in a way that rigidly and explicitly matches only what is on the label, or are they permitted to venture outside of that narrow box, provided they don’t explicitly urge an infringing use?

The Role of Physicians

Perhaps the most interesting nuance in the case is the role of physician sophistication and market realities. In the real world, physicians are highly educated consumers. When a generic hits the market for a drug where the vast majority of the brand’s sales are driven by a patented, off-label use (like Vascepa’s CV indication), doctors already appreciate that the generic can be used for that same cardiovascular benefit. If the market reality is that physicians will foreseeably prescribe the generic for the patented use regardless, how do we weigh that sophisticated prior knowledge against the generic’s marketing materials when determining the specific intent to induce?

This has significant implications for discovery and settlement leverages. Hikma comes to the Court at the Rule 12(b)(6) stage. If the Federal Circuit’s application of Iqbal and Twombly stands, it sets a relatively low bar for brand manufacturers to survive a motion to dismiss simply by pointing to standard industry marketing vernacular like “generic equivalent.” Once past the pleading stage, the astronomical costs of discovery in these high-stakes pharma cases frequently force early settlements. If non-label conduct and physician assumptions can so easily trigger liability, generics will face greater uncertainty, potentially chilling the very market access Hatch-Waxman was designed to encourage.

Of course, there is a flip side. Brand manufacturers invest hundreds of millions in R&D and follow-on clinical trials to discover new, life-saving indications for existing drugs. If a generic can bypass method patents by merely stripping an indication from a label while winking at the market through its sales materials, it severely weakens IP protection and disincentivizes future follow-on clinical development.

Picking a Standard for Intent

The Supreme Court took this case precisely because they need to address a critical loophole: What happens when a generic manufacturer’s label says one thing (compliance), but its public-facing behavior—press releases touting “generic equivalence,” websites referencing total brand sales driven by the patented use, and broad marketing categories—says another?

If a compliant label was an absolute shield, the case would have died at the motion to dismiss stage. Because the Federal Circuit allowed Amarin’s “totality of the circumstances” argument to pierce that statutory armor, the Supreme Court must now decide if, and when, extra-label communications can override the protections of a perfectly executed skinny label.